Tuesday, February 15, 2011

Novartis to commercialise pancreas disease vaccine


Intervet/Schering-Plough Animal Health has granted Novartis Animal Health exclusive rights to part of its patent portfolio for pancreas disease (PD) vaccines. The agreement paves the way for Novartis Animal Health to commercialise a new pancreas disease vaccine based on innovative vaccine technology.

This will potentially offer salmon producers in Norway, the UK and Ireland a unique alternative for managing this costly disease, which is prevalent in these countries. In 2008, Intervet/Schering-Plough Animal Health introduced its current vaccine for pancreas disease, Norvax® Compact PD. This whole virus-based vaccine is currently used successfully in over 100 million salmon in Norway each year. Read more ...

This blog is written by Martin Little The Aquaculturists, published and supported by the International Aquafeed Magazine from Perendale Publishers.

Enhanced by Zemanta

No comments:

Post a Comment

Post a Comment